#1 Clinical Trials Search in Europe

Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors

This article discusses the use of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in clinical trials for heart failure treatment. SGLT2 inhibitors are a class of medications originally developed for diabetes management but have shown promising results in treating heart failure. The focus is on a specific trial that investigates the discontinuation of beta-blockers in patients with recovered heart function while continuing SGLT2 inhibitor therapy.

Table of Contents

What are SGLT2 Inhibitors?

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of medications used primarily in the treatment of certain cardiovascular and metabolic conditions. These drugs, also known as gliflozins, are relatively new in the field of medicine and have gained attention for their unique mechanism of action and potential benefits.[1]

How do SGLT2 Inhibitors Work?

SGLT2 inhibitors work by targeting a specific protein in the kidneys called sodium-glucose co-transporter 2. This protein is responsible for reabsorbing glucose (sugar) from the urine back into the bloodstream. By inhibiting this protein, SGLT2 inhibitors cause more glucose to be excreted through urine, effectively lowering blood sugar levels.[1]

Medical Conditions Treated

SGLT2 inhibitors are primarily used to treat the following conditions:

  • Type 2 Diabetes: These medications help lower blood sugar levels in people with type 2 diabetes.
  • Heart Failure: Recent studies have shown that SGLT2 inhibitors can be beneficial for patients with heart failure, particularly those with reduced ejection fraction (HFrEF).[1]
  • Chronic Kidney Disease: Some SGLT2 inhibitors have shown promise in slowing the progression of chronic kidney disease in certain patients.

Benefits and Effectiveness

SGLT2 inhibitors have demonstrated several potential benefits:

  • Improved Glycemic Control: They help lower blood sugar levels in people with type 2 diabetes.
  • Cardiovascular Protection: Studies have shown that these medications can reduce the risk of major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
  • Weight Loss: Due to the increased excretion of glucose in urine, patients may experience modest weight loss.
  • Blood Pressure Reduction: SGLT2 inhibitors can help lower blood pressure in some patients.
  • Renal Protection: Some studies suggest these medications may help slow the progression of kidney disease in certain patients.

Administration and Dosage

SGLT2 inhibitors are typically taken orally, usually once daily. The specific dosage can vary depending on the particular medication and the patient’s condition. In the clinical trial information provided, it’s mentioned that the maximum daily dose amount is 10 mg, with a maximum total dose amount of 10.92 g over a treatment period of up to 156 weeks.[1]

Potential Side Effects

While SGLT2 inhibitors are generally well-tolerated, they can cause some side effects. Common side effects may include:

  • Urinary Tract Infections: Due to increased glucose in the urine
  • Genital Mycotic Infections: Such as yeast infections
  • Increased Urination: Which can lead to dehydration if not managed properly
  • Low Blood Pressure: Especially when starting the medication
  • Diabetic Ketoacidosis: A rare but serious complication

It’s important to discuss any potential side effects with your healthcare provider.

Ongoing Research

Research on SGLT2 inhibitors is ongoing, with studies exploring their potential benefits in various conditions. For example, the clinical trial information provided (BONFIRE study) is investigating the effects of discontinuing beta-blockers in heart failure patients with recovered left ventricular ejection fraction who are also taking SGLT2 inhibitors.[1]

This study aims to assess whether patients who have recovered from heart failure can safely stop taking beta-blockers while continuing other medications, including SGLT2 inhibitors. The researchers will be monitoring various outcomes, including heart failure relapse, cardiovascular events, and quality of life measures.

Such ongoing research helps to further our understanding of how SGLT2 inhibitors can be best used in combination with other treatments to manage complex cardiovascular conditions.

Aspect Details
Study Title BONFIRE – Beta-blockers discontinuation in patients presenting heart failure with recovered left ventricular ejection fraction
Main Objective To demonstrate the non-inferiority of Beta-Blockers therapy discontinuation in patients with recovered heart function
Key Inclusion Criteria – Age ≥ 18 years
– Established HF diagnosis for >12 months
– Normalized LVEF (≥ 50% for last 6 months)
– Currently on beta-blockers and optimal medical therapy (including SGLT2 inhibitors)
Primary Endpoint Composite of HF relapse and adverse cardiovascular outcomes
Role of SGLT2 Inhibitors Part of the guideline-directed optimal medical therapy for heart failure patients
Study Design Randomized trial comparing beta-blocker discontinuation vs. continuation
Follow-up Duration 1-year minimum, 4-year maximum

FAQ

  • What are SGLT2 inhibitors? SGLT2 inhibitors are a class of medications that were originally developed to treat type 2 diabetes. They work by helping the kidneys remove excess sugar from the body through urine. Recent studies have shown that these drugs also have beneficial effects on heart health, particularly in patients with heart failure.
  • How are SGLT2 inhibitors being used in heart failure treatment? In this clinical trial, SGLT2 inhibitors are part of the guideline-directed optimal medical therapy for heart failure patients. They are being used in combination with other medications to treat patients who have recovered their heart function after previously having reduced left ventricular ejection fraction.
  • What is the main objective of the clinical trial involving SGLT2 inhibitors? The main objective of this trial is to determine if it's safe to discontinue beta-blocker therapy in heart failure patients with recovered left ventricular ejection fraction while continuing other treatments, including SGLT2 inhibitors. The study aims to show that stopping beta-blockers doesn't lead to worse outcomes compared to continuing them.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with a history of heart failure for more than 12 months, who have shown improvement in their heart function (LVEF ≥ 50% for at least 6 months). They must be currently taking beta-blockers and other heart failure medications, including SGLT2 inhibitors, for at least 12 months.
  • What are the potential benefits of using SGLT2 inhibitors in heart failure treatment? While this specific trial doesn't focus on the benefits of SGLT2 inhibitors alone, these medications have shown promise in reducing hospitalizations and improving outcomes in heart failure patients. By including SGLT2 inhibitors as part of the optimal medical therapy, researchers are exploring how these drugs can contribute to maintaining heart health even when other medications, like beta-blockers, are discontinued.

Ongoing Clinical Trials on Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors

  • Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • SGLT2 inhibitors: Sodium-Glucose Co-Transporter 2 inhibitors are a class of medications that help remove excess sugar from the body through urine. Originally developed for diabetes treatment, they have shown benefits in heart failure management.
  • Heart Failure (HF): A condition where the heart cannot pump blood effectively to meet the body's needs. It can be caused by various factors and may lead to symptoms like shortness of breath and fatigue.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction. It's expressed as a percentage and is used to assess heart function.
  • Beta-blockers: A class of medications that slow heart rate and reduce blood pressure. They are commonly used in heart failure treatment.
  • NYHA Functional Class: New York Heart Association Functional Classification, a system used to categorize the extent of heart failure based on symptoms and physical limitations.
  • NT-proBNP: N-terminal pro-B-type natriuretic peptide, a blood marker used to diagnose and monitor heart failure.
  • Guideline-directed optimal medical therapy: The best treatment approach for a condition based on current medical guidelines and research evidence.

References

  1. http://clinicaltrials.eu/trial/study-on-stopping-beta-blockers-in-heart-failure-patients-with-recovered-heart-function-using-carvedilol-and-drug-combination/